The newly approved intranasal ketamine derivative helps fill clear gaps in short-term therapy, says one expert, but questions remain around its long-term effects and affordability.
Ketamine for treatment-resistant depression will be the No. 7 most influential medical innovation in 2017, predict experts at Cleveland Clinic.
Ketamine has emerged as an alternative to electroconvulsive therapy for treatment-resistant depression, but no study has compared the two. A major research project led by Cleveland Clinic is changing that.
Rett syndrome is a rare but debilitating genetic neurodevelopmental with no cure. Cleveland Clinic and Case Western Reserve University researchers are exploring ketamine as a possible treatment.